July 22, 2009 / 11:45 PM / 10 years ago

Takeda: US FDA extends alogliptin-Actos drug review

TOKYO, July 23 (Reuters) - Takeda Pharmaceutical Co Ltd (4502.T) said on Thursday that the U.S. Food and Drug Administration has extended its review of Takeda’s fixed-dose diabetes drug combing alogliptin and Actos to Sept. 4. The FDA had asked Takeda to conduct an additional cardiovascular safety trial for alogliptin in June. (Reporting by Mayumi Negishi)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below